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Blood platelets change shape (from small round spheres to larger 
spread forms) as they participate In thrombosis. Using an electron mi- 
croscopic technique, we surveyed 14 patients with both acute and 
chronic ischemic heart disease; each had increased spread platelet 
forms (69 f 22.2 [standard deviation] percent) when compared with 
14 asymptomatic control subjects (P <O.OOl). When platelets from 
these 14 control subjects were exposed to plasma from the patients 
with ischemic heart disease, spread forms increased from 13.4 f 9.1 
to 44.5 f 15.5 percent (P <O.OOl). There was no significant increase 
in spread platelets in these control subjects when their blood was 
mixed with plasma from another control group. Similar studies were 
performed in seriously ill noncardiac patients; 9 of 13 had increased 
spread platelet forms when compared with control subjects, but plas- 
ma from only 5 of these 9 subjects caused increased spread forms 
when mixed with platelets from normal subjects (P <0.05). 
Thus a factor existed in the plasma of these patients with ischemic 
heart disease that caused normal platelets to become spread. Similar- 
ly the plasma of some patients with serious noncardiac disease had a 
comparable effect on normal platelets. Although the identity of this 
factor is unknown, it is probably unrelated to hormonal or therapeutic 
influences occurring either during acute infarction or during the stress 
of serious illness because (1) the effect of the plasma from patients 
with acute ischemic heart disease was identical to that of patients with 
chronic ischemlc heart disease, and (2) the effect was not present in 
all patients with serious noncardiac disease. 
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Blood platelets change shape as they aggregate. This fact has been 
confirmed by several investigators utilizing transmission’*z and scan- 
ning” electron microscopes. Such changes in configuration. from ._, . . 
round dense disks that develop extrusions or pseudopods to large less 
dense spread forms, may be assessed accurately using an electron mi- 
croscopic technique’ 
To explore further this platelet response, we used this method to 
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control subjects. Similar studies were performed using platelet-poor 
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Materials and Methods 
Patient Selection 
Acute myocardial infarction: Seven patients admitted 
consecutively to the Cardiac Care Unit of the University of 
Michigan Hospital were studied. Acute myocardial infarc- 
tion had been confirmed by appropriate electrocardio- 
graphic and serum enzyme changes. Platelet studies were 
performed within 48 hours of admission. The age range was 
40 to 71 years (mean 56 years). There were five men and 
two women. 
Chronic ischemic heart disease: Seven patients with 
either healed myocardial infarction (occurring more than 3 
months previously) or chronic angina pectoris were stud- 
ied. The age range was 43 to 76 years (mean 54 years). 
There were six men and one woman. 
Control Subjects 
Volunteers from hospital personnel without symptoms of 
cardiovascular illness were selected during the study of 
each patient. These control subjects were excluded if they 
had ingested aspirin-containing drugs or antihistaminic 
agents within the preceding 7 days. In addition, women 
using oral contraceptive agents were exempted. These 
subjects were not age-matched with patients and base-line 
electrocardiograms were not obtained from them. 
Whole Platelet Morphologic Studies 
Peripheral blood samples were obtained by venipuncture 
and collected into sterile disposable syringes. The first 2 ml 
was withdrawn and the syringe detached. A second syringe, 
containing 1 ml of 3.8 percent sterile sodium citrate, was 
immediately attached to the tubing and 9 ml of whole 
blood was withdrawn. The anticoagulant agent was mixed 
gently and briefly with the whole blood sample. Finally, the 
mixture was transferred to a 6 oz. polyethylene wide- 
mouthed bottle. A nonfrosted microscope slide, coated pre- 
viously with a thin film of Formvarm (1 percent polyvinyl 
Formvar in ethylene dichloride), was introduced into the 
bottle, which was placed horizontally in a 37O C oven for 
exactly 8 minutes. The slide was then immersed in cold 1 
percent buffered osmium fixative for 15 minutes at room 
temperature to stabilize the cellular elements that had ad- 
hered to the Formvar film. After fixation, the slide was 
rinsed in several changes of distilled water and then dried. 
Next, the edges of the slide were scraped with a no. 22 
Bard-Parker blade to free the Formvar film. The platelet 
population adhering to the surface of the film was surveyed 
with a phase microscope, and stainless, 200 mesh specimen 
grids were placed over representative areas. Specimen grids 
were placed so that their concave surfaces contacted the 
Formvar film. A thin film of condensed moisture was 
formed over the film by vigorous exhaling at close range. 
Immediately, a piece of plastic tape was stretched over the 
preparation and rubbed firmly. When the tape was re- 
moved, the Formvar film became detached from the sur- 
face of the slide and covered the concave surface of the 
specimen gri,ds. Adherent platelets on the surface of the 
Formvar film ‘were in contact with the surface of the grids, 
which were removed by rimming their circumference with a 
blade and then lifting with a pair of tweezers. Preparations 
were then viewed with an electron microscope. 
Platelet Types 
Blood platelets that adhered to the surface of a Formvar 
film during the 8 minutes of incubation exhibited dtructur- 
al alterations including the extrusion of pseudopodia, hy- 
FIGURE 1. Electron micrograph of three dendritic platelets, indicat- 
ing only minimal platelet activation. (X5,100, reduced by 35 per- 
cent.) 
FIGURE 2. Electron micrograph of five platelets. A round form, la- 
beled R, is superimposed over one spread platelet(S), and a dendritic 
form, labeled D. is contiguous with a spread platelet form. Spread 
forms indicate increased platelet activation. (X5.100, reduced by 39 
percent.) 
alomeric fusion and hyalomeric spreading. Three distinct 
types of platelets were observed. The round type was com- 
pact, had a smooth contour and was uniformly electron- 
dense. Dendritic types were characterized by a compact 
electron-dense central area from which were extruded ei- 
ther a few short blunt pseudopodia or several long pseudo- 
podia (Fig. 1). The spread type was increased in size with 
only a few of the pseudopodial tips obvious. The central 
area was less dense or was entirely electron-translucent 
(Fig. 2). 
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TABLE I 
Clinical Data and Percent Spread Platelets from 13 
































Chronic renal 48 
insufficiency 






Suicide attempt (coma) 48 
Tracheotomy 63 
Pneumonitis 38 
Possible brain tumor 57 












18.5 ztz 5.8 
SD = standard deviation. Plasma Transfer Experiments 
One hundred successive platelet types were categorized. 
A platelet differential count was performed twice on each 
blood sample, and the mean of two observations was ob- 
tained. To avoid the possibility of bias, each grid contain- 
ing platelets for examination was coded so that the person 
surveying the grid was unaware of the source of the sample. 
Such labeling was not performed by those making the elec- 
tron microscopic observations. 
Plasma Transfer Experiments 
After selection of the patient, blood was removed to de- 
termine ABO blood group and Rh type. Two asymptomatic 
subjects with the same blood type were then selected. An 
ABO and Rh cross-match was made between each of these 
three subjects to avoid the potential of platelet activation 
due to the formation of antigen-antibody complexes. 
The following procedures were then performed: 
I. In each of the three subjects to be studied (patient, 
control subject 1, control subject 2): 
A. 3 ml of blood was removed for platelet count. 
B. 9 ml of blood was prepared for whole mount 
platelet study as described. 
II. From the patient and control subject 2: 
A. 9 ml of blood was drawn into a syringe to provide 
3 ml of platelet-poor plasma, which was subse- 
quently maintained at room temperature. 
III. The following studies were then performed: 
A. From the patient, 6 ml of blood was drawn into a 
syringe preloaded with 1 ml of sodium citrate 
and with 3 ml of platelet-poor plasma from con- 
trol subject 2. The sample was then prepared for 
electron microscopic examination of platelets. 
B. From control subject 1: 
6 ml of blood was drawn into a syringe pre- 
loaded with 1 ml of sodium citrate and 3 ml of 
platelet-poor plasma derived from the pa- 
tient. This sample was subsequently prepared 
for electron microscopic examination of plate- 
lets. 
6 ml of blood was drawn into a syringe pre- 
loaded with 1 ml of sodium citrate and 3 ml of 
platelet-poor plasma harvested from control 
subject B. This sample was subsequently pre- 
pared for examination in the electron micro- 
scope. 
Volunteers designated control subject 1 were separated at 
random into control groups A and C. Those designated 
control subject, 2 were separated into control groups B and 
D (see Results). 
Results 
The seven patients with acute myocardial infarc- 
tion had a preponderance of spread platelet forms 
(71.2 f 19.3 [standard deviation] percent), as did the 
seven patients with chronic ischemic heart disease 
(68.6 f 16.4 percent) (four with chronic angina pecto- 
ris, three with healed infarction and one with both). 
No significant correlations were observed between 
the magnitude of platelet activation (numbers of 
spread forms) and the clinical and laboratory status 
(electrocardiograms and serum enzyme, cholesterol 
and triglyceride determinations). 
Patients with ischemic heart disease: A signifi- 
cant increase in the number of spread platelet forms 
was observed when blood from asymptomatic 
subjects (control group A) was exposed to the plate- 
let-poor plasma of patients with ischemic heart dis- 
ease (from 13.4 f 9.1 to 44.5 f 15.5 percent spread 
forms, P <O.OOl) (Fig. 3A). When blood samples 
from these asymptomatic subjects were mixed with 
platelet-poor plasma of another group of asymptom- 
atic subjects (control group B), there was no signifi- 
cant change in the number of spread platelet forms 
(Fig. 3B). However, when plasma from asymptomatic 
control subjects was mixed with platelets from pa- 
tients with ischemic heart disease, no significant de- 
crease in the number of spread forms was observed 
(from 60.9 f 22.2 percent to 49.3 f 26.6 percent). 
Studies in seriously ill patients without heart 
disease: Table I lists the age, sex, condition and 
platelet differential counts for each of the 13 subjects 
with serious illness of noncardiac origin. Patients 1 to 
9 demonstrated a significant increase in number of 
spread forms (54.2 f 17.7 percent), but patients 10 to 
13 had a normal number of spread forms (18.5 f 5.8 
percent). 
The plasma from the patients without cardiac dis- 
ease was mixed with the blood of asymptomatic con- 
trol subjects (group C) and a variability in platelet 
response was observed. When platelet-poor plasma 
from Patients 1 to 9 was mixed with the platelets 
from control subjects (control group C) there was a 
generalized increase in percent of spread forms (from 
19.8 f 9.6 percent to 35.3 f 19.1 percent). This 
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FIGURE 3. Change in percent of spread platelets from control 
subjects (group A). A, before and after mixing with plasma from pa- 
tients with ischemic heart disease. Control values are to left, and re- 
sults after mixing are to the right of the vertical axis. There is a sig- 
nificant increase in spread platelets after exposure to patient plasma 
(P <O.OOl). B, before and after mixing with plasma from other con- 
trol subjects (group B). SD. = standard deviation. These data dem- 
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FIGURE 4. Change in percent of spread platelets. A, from control 
subjects (group Cl) before and after mixing with plasma from nine 
seriously ill patients without underlying cardiac illness. Each of these 
nine patients had an increased percent of spread platelets (mean 
54.2 f 17.7 percent). The change in total number of spread forms 
approaches statistical significance (P <0.05), but there is greater 
variability for each individual experiment (in four subjects there was 
no change or a slight decrease in percent spread forms). B, from the 
same control subjects before and after mixing with plasma from 
other control subjects (group Dl). The change is not significant. 
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% SPREAD PLATELETS 
Mean 17.0 (N=41 18.5 
S. D. 215.0 t7.9 
% SPREAD PLATELETS 
Mean 17.0 (N=4) 25.0 
S.D. f15.2 t12.9 
FIGURE 5. Change in percent of spread piatelets. A, from control 
subjects (group C2) before and after mixing with plasma from four 
seriously ill patients without cardiac disease and a normal number of 
spread platelets (18.5 f 5.8 percent). B, from the same control 
subjects before and after mixing with plasma from other control 
subjects (group D2). There is no significant change after mixing in ei- 
ther study. 
change appeared to be statistically significant at the 
0.05 level, using the Wilcoxon Signed Rank test4 (Fig. 
4A). A control experiment in which platelets from 
control group C were exposed to plasma from another 
control group resulted in no significant change in 
percent of spread platelets (Fig. 4B). Patients 10 to 
13 had no indication of platelet activation and there 
was no detectable difference in spread platelet forms 
from control group blood when exposed to plasma 
from these patients (Fig. 5, A and B). 
Discussion 
Platelet Function and Vascular Disease 
Clumping and fusion of blood platelets are the ear- 
liest visible manifestations of arterial thrombosis. Ac- 
cordingly, investigations into the function and struc- 
ture of platelets have been pursued actively for at 
least two practical reasons: first, because inhibition 
of platelet aggregation may be a possible means of 
preventing arterial thrombosis and, second, because 
it is possible that the continual laying down of micro- 
thrombi on the intimal surface of arteries represents 
an important and fundamental cause of atherosclero- 
sis.” 
The evidence that platelet function is altered in 
patients with atherosclerotic vascular disorders is 
contradictory. We have observed increased spread 
platelet formation in all of a group of patients with 
acute myocardial infarction and in approximately 50 
percent of these patients for up to 18 months after 
infarction.“p7 Similarly, the majority of a group of pa- 
tients with chronic angina pectoris had increased 
spread forms.8 Recently, Salky and Dugdales ob- 
served persistent platelet hyperresponsiveness to col- 
lagen in 5 of 47 patients with ischemic heart disease 
10 to 16 months after infarction. Other investigators 
have demonstrated increased platelet adhesiveness or 
platelet aggregation, or both, in ischemic heart dis- 
ease by using various methods of measuring platelet 
function; these include rotating aliquots of platelet- 
rich plasma at 33 revolutions/min at an angle of 45’ 
in the refrigerator,lO measuring the length and weight 
of a thrombus within a closed rotating circular plastic 
loop,ll observing the stressed template bleeding time 
and the amount of platelet retention in a column of 
glass beads,12 and tabulating the number of platelet 
aggregates in the coronary circulation of patients who 
died sudden1y.l” Other investigators found no detect- 
able change in platelet adhesiveness or platelet func- 
tion by studying adenosine diphosphate-induced 
platelet adhesiveness to glass beads,14,15 measuring 
platelet survival by the chromium-51 method,16 or 
observing platelet aggregometry using the commer- 
cially available aggregometer.‘” 
Another approach to the problem of defining the 
relation of platelet function and vascular disease was 
described by Bolton et al.,17 who identified in the 
plasma from patients with arterial disease a “trans- 
ferable factor” that caused an abnormal sensitivity to 
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adenosine diphosphate by normal platelets.17 These 
investigators concluded that this factor had two com- 
ponents-(l), a low density lipoprotein, the active 
moiety of which was lecithin, and (2) an enzyme that 
converted the lecithin to lysolecithin. They speculat- 
ed that the lysolecithin induced an abnormal platelet 
sensitivity to adenosine diphosphate as measured by 
a maximal increase in platelet electrophoretic mobili- 
ty. A subsequent report has described an “aggregat- 
ing material” in the plasma of “healthy individu- 
als.“ls 
onstrated this effect, yet it was observed in only 5 of 
those 9 patients without heart disease who had an in- 
creased number of spread platelets. This finding in- 
dicates that a preponderance of spread platelet forms 
is not always accompanied by a transferable platelet- 
activating plasma factor. Thus, one might speculate 
that spread platelet formation may be the morpho- 
logic reflection of a final common pathway of func- 
tional platelet response to a number of different 
stimuli. 
Platelet Morphologic Studies 
Our observations depend upon two facts: Platelets 
change shape immediately after blood is removed 
from the circulation, and these changes are a mor- 
phologic expression of platelet surface activation. 
Clearly, the dimensions of the interaction that occurs 
between the platelets and the polyvinyl plastic Form- 
var are unknown; nevertheless, even if this interface 
provides an artificial stimulus for platelet morpho- 
logic change, such provocation is present for blood 
from asymptomatic subjects as well as from patients. 
A plasma factor causing platelet activation: Is 
it valid to conclude that the plasma of patients with 
ischemic heart disease contains a separate and poten- 
tially identifiable factor that causes platelets to be- 
come activated? Although the control experiments 
disclosed no signs of increased platelet activity when 
plasma from asymptomatic subjects was mixed with 
normal platelets, there was a discrepancy between 
the mean age and age range of the control subjects 
and those patients who were studied. It is thus con- 
ceivable that the plasma factor is a normal accompa- 
niment of age; this possibility has not been excluded 
by appropriate experiments in which platelets from 
control subjects were exposed to plasma of another 
group of control subjects, each age-matched for the 
patients under study. However, this seems highly un- 
likely to us since in a survey of 18 asymptomatic 
subjects over age 40 years, platelet configuration was 
not significantly different from that in 67 asymptom- 
atic subjects under age 40 years (unpublished data). 
Effect of hormonal and stress situations during 
acute infarction: A further inference from these 
data would be that platelet activation and the trans- 
ferable plasma factor are probably not the direct re- 
sult of hormonal or therapeutic influences during the 
stress of infarction. No significant difference in the 
effect of plasma from patients with chronic ischemic 
heart disease (measured at least 3 months after myo- 
cardial infarction in four patients) and from patients 
with acute infarction was demonstrated. Since higher 
plasma levels of catecholamines occur during the first 
days of acute myocardial infarction,lg we suggest that 
these substances are probably not responsible for the 
changes observed. There were no data to suggest that 
the seven patients with chronic ischemic heart dis- 
ease were under any particular stress that would have 
caused increased plasma catecholamines. 
Similarly, it is well known that plasma catechol- 
amines increase in various stress situations, including 
hemorrhage20 and shock. 21 It is probable that each of 
the 13 seriously ill patients without cardiac disease in 
this series was sufficiently stressed to have high lev- 
els of plasma cat&holamines, yet increased platelet 
activity, and particularly the plasma factor, was 
found in only some of these patients. 
Clearly, further studies are required to identify 
and isolate this plasma factor, to determine its rela- 
tion to the lysolecithin described by Bolton et a1.17 
and to examine whether platelets are uniformly re- 
sponsive to its influence. 
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